#USA #Minimally Invasive #Minnetonka #Monteris Medical #NeuroBlate

Monteris Medical's Groundbreaking Funding Boost

Monteris Medical, a pioneer in the minimally invasive neurosurgery domain, recently announced the successful closure of a $28 million Series E equity funding round. This funding is poised to enhance the company's capabilities in advancing their NeuroBlate® System, a state-of-the-art solution designed for magnetic resonance-guided laser interstitial thermal therapy (LITT). The infusion of capital aims to not only expand their operational reach in the U.S. but also accelerate various growth strategies encompassing technological advancements, clinical research, and market expansion.

The equity round witnessed participation from existing lead investors, InnovaHealth Partners and Birchview Capital, alongside new entrants like OSF Ventures and the Colorado University Healthcare Innovation Fund. These participants are closely affiliated with healthcare systems that already utilize the NeuroBlate technology, demonstrating their intrinsic motivation to invest in solutions that prioritize patient care and clinical effectiveness.

Mayank Taneja, the Vice President of Venture Investments at OSF Ventures, expressed their commitment to back innovative organizations that deliver substantial advancements in healthcare. He highlighted that the firsthand experience of their clinicians with Monteris' technology underscores the real-world impact and transformational potential of the NeuroBlate system.

In addition to the equity financing, Monteris Medical also secured a new $35 million credit facility from Trinity Capital, enabling them to refinance existing debts effectively. This financial restructuring signifies a robust confidence in the company's operational momentum and its trajectory toward profitability. Rob Lake, Senior Managing Director of Life Sciences at Trinity Capital, noted that Monteris Medical has distinguished itself as a leader in its category, and they anticipate contributing to the company's future growth phases.

The recent financing comes at a pivotal moment for Monteris Medical as the demand for minimally invasive surgical options continues to rise, particularly for patients coping with brain tumors and drug-resistant epilepsy. The NeuroBlate® System utilizes advanced laser technology for precise tissue ablation, thereby offering patients shorter hospital stays, reduced complication rates, and improved post-operative outcomes. Research indicates that this innovative approach leads to outcomes comparable to those achieved with traditional open surgical methods.

Monteris Medical has successfully installed its NeuroBlate technology in nearly 130 health systems across North America, affirming its established footprint in the industry. The system is designed to cater to both adults and children aged two and older, targeting abnormal brain tissues while ensuring safety and precision.

As the company gears up for its next chapter, the ongoing support from both new and established investors is a clear validation of the confidence in NeuroBlate and the overall strategy laid out by Monteris. Richard Emmitt, the board chair of Monteris, remarked on the heightened interest in the NeuroBlate System driven by increasing clinical recognition and demand, solidifying Monteris Medical's position as the go-to partner for neurosurgeons seeking innovative, minimally invasive solutions.

As we look to the future, Monteris Medical stands at the forefront of neurosurgical innovation, driven by a commitment to enhancing patient care through technology and clinical excellence. The combination of their innovative product offerings and strong financial backing paints an optimistic outlook for the sustained advancement of minimally invasive neurosurgery, ultimately providing hope and healing to countless individuals and families.

For more insights on Monteris Medical and the NeuroBlate System, visit monteris.com.